Clinical trials: Coronary Patient
Stable Angina
Safety And Feasibility Study Of Pressure-controlled Intermittent Coronary Sinus Occlusion (PICSO) In Patients With Coronary Artery Disease Undergoing Native Vessel Intervention
Pressure intermittent coronary sinus occlusion (PICSO) in patients with coronary artery disease improves collateral flow index to higher than 30%. PICSO used in this patient population is safe, feasible and effective.
- Trial name
- PICSO (NCT01308125)
- Testing
- PICSO
- Where
- Netherlands
- Volunteers
- 10 people
- Sponsor
- Miracor Medical SA
Diabetes Type 2, Hyperglycaemia (Diabetic)
Effect of Hyperglycaemia and Moxifloxacin on QTc Interval in T2DM
Diabetes is a significant risk factor for sudden cardiac death, with the QTc interval on electrocardiograms (ECGs) often prolonged in diabetic patients due to factors such as hyperglycaemia and insulin resistance.
- Conditions
- Diabetes Type 2, Hyperglycaemia (Diabetic), QT Interval, Variation in, Torsades de Pointes
- Trial name
- NCT07014735
- Testing
- glucose, moxifloxacin
- Where
- United Kingdom
- Volunteers
- 14 people
- Sponsor
- Richmond Pharmacology Limited
Atrial Fibrillation
Xarelto Evidence in Real Life of Patients' Preference and Satisfaction Study
The main objective of the study is to assess preferences of Non Valvular Atrial Fibrillation (NVAF) patients towards different options of an anticoagulation treatment.
- Trial name
- X-PRESS (NCT02876718)
- Testing
- Rivaroxaban (Xarelto, BAY 59-7939)
- Where
- Taiwan
- Volunteers
- 253 people
- Sponsor
- Bayer
Heart Failure, Type 2 Diabetes Mellitus
Effect of Sotagliflozin on Cardiovascular Events in Participants With Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF Trial)
Primary Objective: To compare the effect of sotagliflozin to placebo on the total occurrences of cardiovascular (CV) death, hospitalization for heart failure (HHF), and urgent visit for heart failure (HF) in hemodynamically…
- Trial name
- NCT03521934
- Testing
- Sotagliflozin
- Where
- 466 sites in United States, Argentina and 30 more
- Volunteers
- 1,222 people
- Sponsor
- Lexicon Pharmaceuticals
Aortic Stenosis, Aortic Stenosis, Severe
PARTNER 3 Trial - Aortic Valve-in-Valve
This study will assess the safety and effectiveness of the SAPIEN 3/SAPIEN 3 Ultra transcatheter heart valve (THV) in patients with a failing aortic bioprosthetic valve.
- Trial name
- NCT03003299
- Testing
- Edwards SAPIEN 3/SAPIEN 3 Ultra THV
- Where
- 51 sites in United States, Canada
- Volunteers
- 125 people
- Sponsor
- Edwards Lifesciences
Ventricular Tachycardia
Preventive aBlation of vEntricular tachycaRdia in Patients With myocardiaL INfarction
The BERLIN VT study is designed to evaluate the impact of prophylactic ventricular tachycardia (VT) ablation on all-cause mortality and unplanned hospital admission for congestive heart failure or symptomatic ventricular…
- Trial name
- BERLIN VT (NCT02501005)
- Testing
- VT ablation
- Where
- 5 sites in Germany
- Volunteers
- 163 people
- Sponsor
- Biotronik SE & Co. KG
Kawasaki Disease
Study of Efficacy and Safety of Canakinumab in Pediatric Patients With Kawasaki Disease
The purpose of this trial is to evaluate whether, in Intravenous Immunoglobulin-naïve or refractory patients diagnosed with active Kawasaki disease, administration of canakinumab controls fever and acute phase reactants.
- Trial name
- NCT02980263
- Testing
- Canakinumab
- Sponsor
- Novartis Pharmaceuticals
Essential Hypertension With Stable Angina and Dyslipidemia
A Study to Evaluate the Effects of Azilsartan on Coronary Artery Plaque in Essential Hypertensive Patients With Stable Angina and Dyslipidemia.
The purpose of this study is to evaluate the effects of oral azilsartan once daily for 32 weeks on coronary artery plaque in essential hypertensive patients with stable angina and dyslipidemia.
- Trial name
- ALIVE (NCT02400775)
- Testing
- Azilsartan
- Where
- Japan
- Sponsor
- Takeda
Prevention of Atherothrombotic Events, Coronary Artery Disease (CAD)
Study to Learn More About the Safety and Effectiveness of Rivaroxaban (Xarelto) When Given Together With Acetylsalicylic Acid to Indian People With Narrowing of the Arteries of the Heart (CAD) and/or With Reduced Blood Flow in the Arteries of the Legs and Arms With Symptoms (Symptomatic PAD)
This is an observational study in which data from Indian people with coronary artery disease and / or symptomatic peripheral artery disease who will be receiving the drug rivaroxaban (Xarelto) are studied.
- Conditions
- Prevention of Atherothrombotic Events, Coronary Artery Disease (CAD), Symptomatic Peripheral Artery Disease (Symptomatic PAD)
- Trial name
- NCT04298567
- Testing
- Rivaroxaban (Xarelto,Bay 59-7939), Acetylsalicylic acid(ASA)
- Where
- India
- Volunteers
- 300 people
- Sponsor
- Bayer
Left Ventricular Dysfunction, Coronary Artery Disease
Impella®-Supported PCI in High-Risk Patients With Complex Coronary Artery Disease and Reduced Left Ventricular Function
The purpose of this study is to assess if using the Impella® CP (or Impella® 2.5) device during high-risk PCI in patients with reduced left-sided heart function will result in an improvement in symptoms, heart function and health…
- Trial name
- PROTECT IV (NCT04763200)
- Testing
- Impella CP® / Impella CP® with SmartAssist® / Impella 2.5®, IABP Intra-aortic balloon pump
- Where
- 110 sites in United States, Canada and 5 more
- Volunteers
- 1,252 people
- Sponsor
- Abiomed Inc.
Stable Angina, Myocardial Infarction
Safety Evaluation of Clopidogrel Sulfate in Patients With Stable Angina/Old Myocardial Infarction to Whom Percutaneous Coronary Intervention is Being Planned
Primary objective: To evaluate whether 12 weeks of clopidogrel is superior to ticlopidine in terms of lower risk of the safety events of interest in patients with stable angina (SA) or old myocardial infarction (OMI) to which…
- Trial name
- CLEAN (NCT00821834)
- Testing
- clopidogrel (SR25990), ticlopidine
- Where
- Japan
- Volunteers
- 1,003 people
- Sponsor
- Sanofi
Hyperkalemia, Heart Failure
Evaluation of Patiromer in Heart Failure Patients
The purpose of this study was to assess the effects of patiromer on serum potassium participants with heart failure. This study also assessed the safety and tolerability of patiromer in participants with heart failure.
- Trial name
- PEARL-HF (NCT00868439)
- Testing
- patiromer
- Where
- 33 sites in United States, Czechia and 5 more
- Volunteers
- 120 people
- Sponsor
- Relypsa, Inc.
Amyloidosis in Transthyretin (TTR), Amyloidosis, Familial
To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE)
The AG10-504 study is an open-label extension study of acoramidis in participants with newly diagnosed transthyretin amyloid cardiomyopathy (ATTR-CM) or both ATTR-CM and transthyretin amyloid polyneuropathy (ATTR-PN).
- Conditions
- Amyloidosis in Transthyretin (TTR), Amyloidosis, Familial, Amyloid Cardiomyopathy, Amyloid Cardiomyopathy, Transthyretin-Related
- Trial name
- NCT07116473
- Testing
- Acoramidis (AG10)
- Volunteers
- 250 people
- Sponsor
- Eidos Therapeutics, a BridgeBio company
Growth Hormone Disorder, Growth Hormone Deficiency in Children
Non-interventional Study of Patients Using Norditropin® for Growth Hormone Deficiency or Turner Syndrome
This study is conducted in Japan. The aim of this study is to collect information about the efficacy and safety of Norditropin® (somatropin) in the long-term treatment of short stature with GHD (Growth Hormone Deficiency) where…
- Conditions
- Growth Hormone Disorder, Growth Hormone Deficiency in Children, Genetic Disorder, Turner Syndrome
- Trial name
- NordiPAD (NCT01604161)
- Testing
- somatropin
- Where
- Japan
- Volunteers
- 2,016 people
- Sponsor
- Novo Nordisk A/S
Atrial Arrhythmia, QT Interval, Variation in
QT Changes as Detected From LINQ ECG During Antiarrhythmic Loading (LINQ QT)
The LINQ QT Study is a prospective, non-randomized, multi-center, observational, post-market clinical study investigating QT interval changes due to antiarrhythmic drug loading.
- Conditions
- Atrial Arrhythmia, QT Interval, Variation in, Arrhythmias, Cardiac
- Trial name
- LINQ QT (NCT05488470)
- Testing
- LINQ/LINQ II
- Where
- 3 sites in United States
- Volunteers
- 22 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Heart Diseases, Rhythm; Abnormal
BIO|CONCEPT.ECG-Library (Collection of ECG Signals for Development of Algorithms)
Collection of Holter surface ECGs for the development of new sensing and detection algorithms
- Trial name
- NCT04243070
- Testing
- 3-channel Holter ECG recording, 12-channel Holter ECG recording
- Where
- 5 sites in Germany
- Volunteers
- 89 people
- Sponsor
- Biotronik SE & Co. KG
Heart Failure, Congestive
ACCLAIM - Advanced Chronic Heart Failure CLinical Assessment of Immune Modulation Therapy
The purpose of this study is to test the safety and efficacy of the Celacade™ system in reducing the risk of mortality and cardiovascular hospitalizations in patients with chronic systolic heart failure.
- Trial name
- NCT00111969
- Testing
- Celacade™ system
- Volunteers
- 2,016 people
- Sponsor
- Vasogen
Angina
Ranolazine SR in Patients With Chronic Angina Who Remain Symptomatic Despite Maximal Treatment With Amlodipine
The study will be a multi-national, double-blind, randomized, placebo-controlled, parallel group study to evaluate the effectiveness of ranolazine (1000 mg twice daily) in approximately 500 patients with chronic angina who remain…
- Trial name
- NCT00091429
- Testing
- Ranolazine
- Volunteers
- 500 people
- Sponsor
- Gilead Sciences
Heart Failure, Sudden Cardiac Death
CORE: Study to Evaluate the Conducted AF-Response-Algorithm in Patients Suffering From Heart Failure and Atrial Fibrillation
The Medtronic InSync III Marquis Cardiac Resynchronization Therapy Defibrillator (CRT-D)-System (implantable cardioverter-defibrillator with biventricular stimulation for cardiac resynchronization) is equipped with the…
- Conditions
- Heart Failure, Sudden Cardiac Death, Atrial Fibrillation
- Trial name
- NCT00170313
- Testing
- Conducted AF-Response Algorithm (CAFR) On, Conducted AF-Response Algorithm (CAFR) Off
- Where
- 7 sites in Germany
- Volunteers
- 100 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Atrial Fibrillation
A Study of the Efficacy and Safety of Vernakalant Hydrochloride (MK-6621) in Patients With Atrial Fibrillation (MK-6621-010 AM4)
This study will investigate if treatment with vernakalant hydrochloride (MK-6621) results in a greater proportion of patients with treatment-induced conversion of Atrial Fibrillation to sinus rhythm compared to placebo.
- Trial name
- NCT01174160
- Testing
- vernakalant hydrochloride
- Volunteers
- 123 people
- Sponsor
- Advanz Pharma
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.